- $18.06m
- -$7.16m
- 28
- 46
- 65
- 43
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.67 | ||
| Price to Tang. Book | 0.67 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -144.12% | ||
| Return on Equity | -89.42% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
LeonaBio, Inc., formerly Athira Pharma, Inc., is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). The Company's lead drug candidates, lasofoxifene and ATH-1105, are novel, small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. ATH-1105 is a novel, orally available, brain-penetrant, next-generation small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for potential treatment of neurodegenerative diseases, including ALS, Alzheimer's disease, and Parkinson's disease. Lasofoxifene is a novel, nonsteroidal SERM with a binding profile, designed to confer potent activity against both wild-type and mutant estrogen receptors, including the clinically significant ESR1 mutations.
Directors
- Mark Litton PRE (53)
- Glenna Mileson CFO (63)
- Rachel Lenington COO (48)
- Kevin Church VPR (36)
- Hans Moebius OTH (65)
- Grant Pickering DRC (53)
- Joseph Edelman IND (65)
- John Fluke IND (78)
- James Johnson IND (64)
- Barbara Kosacz IND (63)
- Kelly Romano IND (59)
- Last Annual
- December 31st, 2024
- Last Interim
- September 30th, 2025
- Incorporated
- October 27th, 2015
- Public Since
- September 18th, 2020
- No. of Shareholders
- 41
- No. of Employees
- 26
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 3,943,887
- Address
- 18706 North Creek Parkway, Suite 104, BOTHELL, 98011
- Web
- https://leonabio.com/
- Phone
- +1 4256208501
- Contact
- Julie Rathbun
- Auditors
- Ernst & Young LLP
Upcoming Events for LONA
LeonaBio Inc Extraordinary Shareholders Meeting
Q1 2026 Athira Pharma Inc Earnings Release
Athira Pharma Inc Annual Shareholders Meeting
Similar to LONA
ABPRO Holdings
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the LeonaBio share price?
As of Today at 20:44 UTC, shares in LeonaBio are trading at $4.58. This share price information is delayed by 15 minutes.
How has the LeonaBio share price performed this year?
Shares in LeonaBio last closed at $4.58 and the price had moved by -11% over the past 365 days. In terms of relative price strength the LeonaBio share price has underperformed the S&P500 Index by -22.63% over the past year.
What are the analyst and broker recommendations for LeonaBio?
The overall consensus recommendation for LeonaBio is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the LeonaBio dividend yield?
LeonaBio does not currently pay a dividend.
Does LeonaBio pay a dividend?
LeonaBio does not currently pay a dividend.
When does LeonaBio next pay dividends?
LeonaBio does not currently pay a dividend.
How do I buy LeonaBio shares?
To buy shares in LeonaBio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of LeonaBio?
As of the previous close price of $4.58, shares in LeonaBio had a market capitalisation of $18.06m.
Where are LeonaBio shares listed?
Here are the trading details for LeonaBio:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: LONA
What kind of share is LeonaBio?
Based on an overall assessment of its quality, value and momentum LeonaBio is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a LeonaBio share price forecast for 2026?
The analyst consensus target price for shares in LeonaBio is $4.00. That is 12.66% below the last closing price of $4.58.
Analysts covering LeonaBio currently have a consensus Earnings Per Share (EPS) forecast of -$6.49 for the next financial year.
Find out moreWhat is the trend in the LeonaBio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like LeonaBio. Over the past six months, its share price has outperformed the S&P500 Index by +7.42%.
As of the last closing price of $4.58, shares in LeonaBio were trading +10.53% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the LeonaBio PE Ratio?
The LeonaBio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.58.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of LeonaBio?
LeonaBio's management team is headed by:
- Mark Litton - PRE
- Glenna Mileson - CFO
- Rachel Lenington - COO
- Kevin Church - VPR
- Hans Moebius - OTH
- Grant Pickering - DRC
- Joseph Edelman - IND
- John Fluke - IND
- James Johnson - IND
- Barbara Kosacz - IND
- Kelly Romano - IND